Nuvectis Pharma (NVCT) Change in Accured Expenses (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of Change in Accured Expenses data on file, last reported at -$460000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 1940.0% year-over-year to -$460000.0; the trailing twelve-month figure through Mar 2026 stood at $866000.0 (up 128.5% YoY), and the FY2025 full-year result was $1.4 million, up 217.88% from the prior year.
• Change in Accured Expenses slipped to -$460000.0 in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.1 million in Q4 2025 to a low of -$863000.0 in Q2 2025.
• A 5-year average of $190411.8 and a median of $154000.0 in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses surged 1271.7% in 2022 and sank 1940.0% in 2026, its largest moves.
• Tracing NVCT's Change in Accured Expenses over 5 years: stood at -$305000.0 in 2022, then soared by 184.26% to $257000.0 in 2023, then soared by 75.1% to $450000.0 in 2024, then jumped by 372.44% to $2.1 million in 2025, then plunged by 121.64% to -$460000.0 in 2026.
• Business Quant data shows NVCT's Change in Accured Expenses at -$460000.0 in Q1 2026, $2.1 million in Q4 2025, and $63000.0 in Q3 2025.